Loading: 30 ng per lane of SARS-CoV-2 (COVID-19) Spike RBD recombinant protein, 10-303. Antibodies: SARS-CoV-2 (COVID-19) Spike RBD, 9087, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 µg/mL and Lane 2: 2 µg/mL.
Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein Antibodies: SARS-CoV-2 (COVID-19) Spike antibody, MBS154650 (1 ug/mL). A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike S1 recombinant protein as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike RBD antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 16 ng/mL to 2000ng/mL.
Coating Antigen: SARS-CoV-2 full length spike proteins, including WT, UK variant (B.1.1.7), SA variant (B.1.135) and Brazil (P.1). Dilution: 10-3000 ng/mL. Incubate at 4 °C overnight.Detection Antibodies: SARS-CoV-2 Spike RBD Antibody, (MBS154650), 2 µg/mL, incubate at RT for 1 hr.Secondary Antibodies: Goat anti-rabbit HRP at 1:20,000, incubate at RT for 1 hr.Immunogen region of antibody (MBS154650) includes site 501N that was mutated in all three variants. 9087 has low binding affinity for all three variants as compared to WT.
Immunohistochemistry Validation of SARSCoV-2 (COVID-19) Spike RBD in COVID-19 Patient Lung Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike RBD antibody (MBS154650, 0.5 µg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 Spike RBD protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.